ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19

Overview

The purpose of this study is to evaluate the feasibility, acceptability and effectiveness of a brief, telehealth intervention (the Emotional Support Plan), intended to support autistic adults to cope with their negative emotions during and/or after the COVID-19 pandemic. The first objective is to develop and refine a brief telehealth-delivered treatment, the Emotional Support Plan (ESP), to help promote adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic. The second objective is to assess the feasibility and effectiveness of the ESP to support autistic adults to implement emotion regulation strategies during periods of acute distress. The last objective is to yield preliminary data to apply for extramural grants to validate these methods to monitor and support mental health of autistic adults during key transitions (e.g., starting college).

Full Title of Study: “ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19 (Coronavirus Disease)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 9, 2022

Interventions

  • Behavioral: Emotional Support Plan
    • The Emotional Support Plan (ESP) is designed to help adults to cope during periods of acute distress, such as those experienced during the COVID-19 pandemic.
  • Behavioral: Daily Monitoring
    • The daily monitoring will remind participants 4x/day to report on their mood, distress, etc. and use their ESP if needed.

Arms, Groups and Cohorts

  • Experimental: Emotional Support Plan (ESP) + Weekly Monitoring
    • This will involve weekly assessments without prompting to use the plan.
  • Experimental: Emotional Support Plan (ESP) + 4x Daily Monitoring
    • Participants in this arm will be prompted on their phones 4x/day randomly, to report on activities, mood, suicidal ideation, distress level and ESP use since the last prompt

Clinical Trial Outcome Measures

Primary Measures

  • Decreased distress on Patient Health Questionnaire (PHQ-9)
    • Time Frame: 8 week study period
    • The PHQ-9, assessed weekly, is a 9-item questionnaire of psychological function over the past week with all items on a “0” (not at all) to “3” (nearly every day) scale. Higher scores equal more distress.
  • Decreased distress on EMA reports
    • Time Frame: 8 week study period
    • EMA (Ecological Momentary Assessment) reports of decreased distress (in ESP + daily monitoring group only). Higher scores on the item equal higher levels of distress.
  • Decreased anxiety symptoms on the Generalized Anxiety Disorder Questionnaire (GAD-7)
    • Time Frame: 8 week study period
    • The GAD-7, assessed weekly, is a 7-item questionnaire of anxiety symptoms over the past week with all items on a “0” (not at all) to “3” (nearly every day) scale. Higher scores equal more anxiety.

Secondary Measures

  • Adult Self Report (ASR)
    • Time Frame: 8 week study period
    • The ASR is a measure of adaptive functioning and psychopathology (e.g., anxiety, depression symptoms). Most of the items are on a 3 point scale including: (0) Not true, (1) Somewhat or sometimes true, and (2) Very often or often true.

Participating in This Clinical Trial

Inclusion Criteria Adults 18 years or older with previously established diagnoses in ASD will be invited to participate. Adults who have a verbal IQ above 70 or who are students admitted to a college or university will be included in the study. Exclusion Criteria

  • Individuals who are younger than 18 years old or who does not have diagnosis of ASD will excluded from the study as the purpose of the current research is to evaluate the validity of ESPs in adults with autism. – Adults who are unable to understand English will be excluded because the instruments being investigated are currently only validated in English and the study team is not sufficiently fluent in other languages to provide assurance that informed consent could be obtained (or intervention provided) in a language besides English. – Subjects without access to a compatible iOS and Android smartphone (nearly all phones from the past 10 years are compatible) will be excluded because the study requires subjects to record responses on a smartphone app. Individuals will not be excluded from the study based on race, ethnicity or gender. – Subjects who have a verbal IQ below 70 will be excluded as this is a study that requires self-report and engagement in a one-on-one intervention. – If the PI's clinical judgment is that it would not be in the adult's best interest to be enrolled, they may also be excluded.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Rutgers, The State University of New Jersey
  • Provider of Information About this Clinical Study
    • Principal Investigator: Vanessa H. Bal, PhD, Assistant Professor – Rutgers, The State University of New Jersey

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.